Join ASPHO's Industry Relations Council
Work with your target audience to advance pediatric hematology/oncology
As an organization that supports ASPHO’s mission and goals, your company is eligible to join ASPHO’s Industry Relations Council (IRC) to enjoy year-round benefits.
As an IRC member, you’ll gain:
- Expanded access to ASPHO leadership
- Ongoing visibility and recognition
- Exclusive discounts
- Opportunities to collaborate with ASPHO and its membership to improve patient care
Tiered participation ensures companies of all sizes benefit by joining ASPHO's IRC. Your company can join at the associate, executive, or premier level to take advantage of the benefits that best fit your needs, from newsletter advertising to 3-hour advisory board or focus group meetings.
Apply to join ASPHO's IRC today. For more information, contact This email address is being protected from spambots. You need JavaScript enabled to view it. .
Join These Companies on ASPHO's Industry Relations Council
Platinum Level
Alexion
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a
leader in rare diseases for more than 30 years, Alexion is focused on serving patients
and families affected by rare diseases and devastating conditions through the
discovery, development, and commercialization of life-changing medicines. Alexion
focuses research efforts on novel molecules and targets that include the complement
cascade, and development efforts in hematology, nephrology, neurology, metabolic
disorders, cardiology, and ophthalmology. Headquartered in Boston, Massachusetts,
Alexion has offices around the globe and serves patients in more than 70 countries. To
learn more, please visit www.alexion.com.
Alexion is committed to helping your patients access the care they need. OneSource™ is
a free, personalized patient support program offered by Alexion. Whether your patient is
newly diagnosed or has had their condition for some time, our specialists are available
for patients and their caregivers. We can help them make sense of their health
insurance coverage, answer questions about treatment and connect them to community
resources. We’re committed to helping your patients start and stay on track with
their prescribed treatment. To learn more visit www.alexiononesource.com.
Executive Level
bluebird bio
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. To learn more, visit https://www.bluebirdbio.com/.
For patients considering a bluebird bio gene therapy, there’s my bluebird support. my bluebird support is staffed by Patient Navigators who can provide resources, help answer questions, and assistance with next steps throughout the treatment journey. Available at no cost, enroll your patient online to start the conversation.
Servier
Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.
As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-treat cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves. Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition.
At Servier, we are committed to ensuring that all patients can access necessary treatments, regardless of their financial situation. Our Patient Assistance Program for Oncaspar and Asparlas is designed to support patients facing affordability challenges, whether they are under-insured or uninsured. To begin the enrollment process, healthcare providers can call 1-800-813-5905. Our goal is to remove financial barriers and ensure that every patient receives the treatment they need.
For more resources and information, please visit our website at ServierONEforall.com. Additionally, you can explore ServierONE.com to learn more about our services and download further resources. These platforms provide comprehensive support and information tailored for both patients and healthcare providers. By leveraging these resources, we aim to offer robust assistance and make the process as seamless as possible for those in need.
For other ways to support or partner with ASPHO, review our corporate support opportunities.